ArticleInternational journal of environmental research and public health2020

Using the Systemic Immune-Inflammation Index (SII) as a Mid-Treatment Marker for Survival among Patients with Stage-III Locally Advanced Non-Small Cell Lung Cancer (NSCLC).

Tithi Biswas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.